Guardant Health, INC Form 4 insider transactions

Guardant Health Director Manuel Hidalgo Medina sold 2,165 shares of common stock for a weighted average price of $54.1574 per share.

Guardant Health's Co-Chief Executive Officer, Helmy Eltoukhy, sold 300,000 shares of common stock for approximately $17.8 million through a pre-planned trading arrangement.

Guardant Health Director Meghan V. Joyce sold 100 shares of common stock for $65.84 per share, executed under a pre-arranged Rule 10b5-1 plan.

Guardant Health's Chief Legal Officer, John G. Saia, acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the acquisition of common stock through RSU vesting and the subsequent disposition of shares for tax purposes.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Guardant Health Director Steve Krognes reported the vesting of 155 restricted stock units into common stock on August 31, 2025.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the sale of 2,000 shares of common stock for approximately $123,510.

A director at Guardant Health, Inc. sold 116 shares of common stock for $59.02 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Myrtle S. Potter sold 26 shares of common stock for $59.02 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Manuel Hidalgo Medina converted 232 Restricted Stock Units into common stock, increasing his direct common stock holdings to 3,016 shares.

Guardant Health Director Tariq Musa reported a future acquisition of 250 common shares and 250 restricted stock units, stemming from a pre-existing vesting schedule.

Guardant Health Director Myrtle S. Potter acquired 69 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Meghan V. Joyce reported the acquisition of 67 common shares through the vesting of restricted stock units.

Guardant Health Director Steve Krognes acquired 154 shares of common stock via restricted stock unit vesting.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $48.20 per share on July 17, 2025, as part of a Rule 10b5-1 trading plan.

Myrtle S. Potter, a Director at Guardant Health, Inc., has filed a Form 4 indicating a planned sale of 26 shares of common stock on July 17, 2025, under a Rule 10b5-1 trading plan.

Guardant Health, Inc. Director Manuel Hidalgo Medina acquired 2,784 common shares through the vesting of restricted stock units on July 17, 2025, as part of a previously granted equity award.

Guardant Health, Inc. Director Tariq Musa acquired 250 shares of common stock through the exercise of Restricted Stock Units (RSUs) on July 15, 2025, increasing his direct beneficial ownership to 7,440 shares.

Guardant Health Director Myrtle S. Potter reported the vesting of 68 restricted stock units and the acquisition of 68 shares of common stock on July 15, 2025, increasing her direct beneficial ownership to 18,222 shares.

Guardant Health, Inc. Director Meghan V. Joyce acquired 66 shares of common stock on July 4, 2025, through the vesting of Restricted Stock Units.

Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and a corresponding disposal of shares to cover tax withholding obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the acquisition of shares through Restricted Stock Unit vesting and the subsequent disposition of shares for tax obligations.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent share disposition for tax withholding purposes.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and associated tax withholding transactions on July 1, 2025, as detailed in a recent SEC Form 4 filing.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations.

Guardant Health, Inc.'s Chief Financial Officer, Michael Brian Bell, reported the vesting of restricted stock units and the subsequent disposition of shares to cover tax obligations.

Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, reported the acquisition of common stock through RSU vesting and subsequent sales and tax withholdings, primarily executed under a pre-arranged 10b5-1 trading plan.

Guardant Health, Inc. Director Steve E. Krognes has filed a Form 4 detailing the future vesting of 154 common shares from Restricted Stock Units on June 30, 2025.

Guardant Health, Inc. Co-Chief Executive Officer and Director Helmy Eltoukhy reported the vesting of restricted stock units and subsequent tax-related share dispositions in late June and early July 2025.